Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Tumor-targeted Salmonella Enterica Serovar Agona as Cancer Therapy Agents
Putra Science Park Malaysia flag Malaysia
Abstract ID:
Genetically engineered Salmonella enterica serovar Agona as a better candidate for anti-tumor vector compared to genetically engineered Salmonella enterica serovar Typhimurium...
Contact Ahmad zakir Dato wira jaafar
Participants
You
Email me a copy of this message

Genetically engineered Salmonella enterica serovar Agona as a better candidate for anti-tumor vector compared to genetically engineered Salmonella enterica serovar Typhimurium due to its similar anti-tumor capacity and reduced pathogenicity.

The genetically engineered Salmonella enterica has been the most widely exploited carrier system for use in cancer treatment. Salmonella enterica serovar Typhimurium has been extensively studied for its anti-tumour capacity and it has been clinically proven that it is able to reduce tumor sizes. In our recent study, genetically engineered Salmonella enterica serovar Agona would be a better candidate compared to genetically engineered Salmonella enterica serovar Typhimurium due to its similar anti-tumor capacity and reduced pathogenicity as shown in mice model. Both strains have been genetically engineered at the sopB, sopD and pipD virulence factors which are located in Salmonella Pathogenecity Islands 5 contributed for enteropathogenecity.

According to our in vivo tumor-bearing mice study, genetically engineered Salmonella enteric serovar Typhimurium and Agona exhibited the capacity to inhibit the growth of tumors via intraperitoneal and intratumoral injection of bacteria into tumor-bearing mice. However, genetically engineered Salmonella enteric serovar Agona shows the longest survival after treatment compared to genetically engineered Salmonella enteric serovar Typhimurium. This also reviewed that genetically engineered Salmonella enteric serovar Agona causes milder infections when it is compared to genetically engineered Salmonella enteric serovar Typhimurium. The usefulness of genetically engineered Salmonella enteric serovar Agona as anti-tumor agent over well documented genetically engineered Salmonella enteric serovar Typhimurium should contribute an important platform for the application of genetic engineered Salmonella enteric to be one of great potential organism for the generation of live attenuated biodrug delivery system in cancer therapeutics.

Type of Business Relationship Sought
Licensing and Commercialisation
FEATURED
Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE
UNIVERSITY